NOT MANY PRODUCTS ON THE MARKET HAVE PUBLISHED
PEER-REVIEWED STUDIES
Peer-Reviewed Articles in reputable journals are more reliable than some information from a blog on the internet or on a company website. It's very important to know the difference...
SPONSORED CONTENT
Peer Reviewed Study Publications
Does Protandim Work? Here are answers to that question below.
Dr. Joe McChord Explains the Significance of the Ohio State University Study - Heart Health
Protandim Attenuates Intimal Hyperplasia in Human Saphenous Veins Cultured Ex Vivo via a Catalase-Dependent Pathway
OHIO STATE UNIVERSITY
| Click here for full abstract. |
Free Radical Biology and Medicine (2010)
Abstract: Human saphenous veins (HSV) are widely used for bypass graphs despite their relatively low long-term patency. The role of reactive oxygen species (ROS) signaling in intima hyperplasia (IH), an early stage pathology of vein graft disease, and to explore the potential therapeutic effects of up-regulating endogenous antioxidant enzymes in segments of HSV cultured ex vivo in an established ex vivo model of HSV IH. Protandim®, known to activate Nrf2 and increase the expression of endogenous antioxidant enzymes in several in vitro and in vivo models, was used in this study.
Results: Protandim® inhibits the formation of IH and the increase in cellular proliferation in HSV cultured ex-vivo. Further, Protandim® attenuates rise in superoxide (O) levels in HSV, attenuates rise in lipid peroxidation (4-HNE) levels in HSV, enhances increases in the activities of HO-1, total SOD and catalase in HSV, enhances the protein level and immunofluorescent intensity of catalase in HSV, blocks medial thickening as well as cellular proliferation in established ex-vivo model of the early stages of vein-graft disease. These abilities of Protandim®, as demonstrated in HSV harvested from patients undergoing coronary artery bypass grafting, makes it an attractive candidate for future consideration as a pharmacological treatment of vein-graft failure.
Dr. Joe McCord Explains the Significance of the Baylor University Study - Chemosensitization
Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs.
BAYLOR UNIVERSITY MEDICAL CENTER DALLAS TEXAS
| Click here for full abstract |
Nutrition and cancer. (2010)
Abstract: Chemosensitization has been observed in cancers of the breast, colon, pancreas, gastric, liver, blood, lung, prostate, bladder, cervix, ovary, head and neck, and brain and in multiple myeloma, leukemia, and lymphoma. Similar studies have also revealed that this agent can sensitize a variety of tumors to gamma radiation including glioma, neuroblastoma, cervical carcinoma, epidermal carcinoma, prostate cancer, and colon cancer. How curcumin acts as a chemosensitizer and radiosensitizer has also been studied extensively. For example, it downregulates various growth regulatory pathways and specific genetic targets including genes for NF-κB, STAT3, COX2, Akt, antiapoptotic proteins, growth factor receptors, and multidrug-resistance proteins. Although it acts as a chemosensitizer and radiosensitizer for tumors in some cases, curcumin has also been shown to protect normal organs such as liver, kidney, oral mucosa, and heart from chemotherapy and radiotherapy-induced toxicity.
Summary: The protective effects of curcumin appear to be mediated through its ability to induce the activation of NRF2 and induce the expression of antioxidant enzymes These preclinical studies are expected to lead to clinical trials to prove the potential of this age-old golden spice for treating cancer patients.
The Induction of Human Superoxide Dismutase and Catalase In Vivo: A Fundamentally New Approach to Antioxidant Therapy
UNIVERSITY OF COLORADO DENVER
| Click here for full abstract |
Free Radical Biology and Medicine (2006)
Abstract: We conclude that modest induction of the catalytic antioxidants SOD and catalase may be a much more effective approach than supplementation with antioxidants (such as vitamins C and E) that can, at best, stoichiometrically scavenge a very small fraction of total oxidant production.
Summary: Protandim® completely eliminates the usual age related increase in cell aging markers by decreasing the indicators of oxidative stress (TBARS) by 40% in 30 days, and by increasing cellular production of antioxidant enzymes superoxide dismutase (SOD) by 30% and catalase (CAT) by 54% by 120 days.
Synergistic Induction of Heme Oxygenase-1 by the Components of an Antioxidant Supplement Protandim® (glutathione +300%)
UNIVERSITY OF COLORADO DENVER
| Click here for full abstract |
Free Radical Biology and Medicine (2009)
Abstract: Protandim® is a supplement formulated with the objective of combining multiple phytochemicals at low non-toxic doses to gain synergy for induction of endogenous antioxidant enzymes. All components together produced a strongly synergistic induction of around three to ninefold, greatly exceeding the sum of the parts, and strongly suggesting this may be an effective method for the induction of antioxidant enzymes.
Conclusion: Protandim® produces a 300% increase in the cellular production of glutathione. As a key antioxidant, glutathione plays critical roles in the regenesis of other antioxidants (vitamins C and E), liver detoxification and elimination, and tissue repair. Further, Protandim® was shown to be a Nrf2 Activator. Findings show nuclear translocation of Nrf2 to the Antioxidant Response Element sites of genes on the DNA. Nrf2 then “re-tunes” the associated genes to function optimally.
Protandim, a Fundamentally New Antioxidant Approach in Chemoprevention Using Mouse Two-Stage Skin Carcinogenesis as a Model
LOUISIANA STATE UNIVERSITY
| Click here for full abstract |
PLoS One Journal (2009)
Abstract: Biochemical and histological studies revealed that the Protandim diet suppressed tumor promoter – induced oxidative stress, cell proliferation, and inflammation. “Overall, induction of antioxidant enzymes by Protandim® may serve as a practical and potent approach for cancer prevention.”
Conclusions: Protandim® supplemented mice showed a 33% reduction in skin tumor incidence and a 57% reduction in tumor multiplicity. The mice receiving the diet without Protandim® supplementation developed cancer tumors 100% of the time.
Chronic Pulmonary Artery Pressure Elevation is Insufficient to Explain Right Heart Failure
VIRGINIA COMMONWEALTH UNIVERSITY
| Click here for full abstract |
American Heart Association Journal, Circulation (2009)
Clinical Perspective - Protandim® can prevent Right Ventricular (RV) dysfunction and pathological remodeling in the setting of persistent pressure overload. “Induction of myocardial nuclear factor E2-related factor 2 and heme-oxygenase 1 with a dietary supplement (Protandim®) prevented fibrosis and capillary loss and preserved RV function despite continuing pressure overload.”
Conclusions: “Protandim® also prevented the death of heart cells and significantly lowered osteopontin (OPN-1) levels by more than 50%.” Protandim® has the ability “to effectively activate the transcription factor Nrf2, a signal to the cell’s DNA to increase expression of a network of antioxidants, anti-inflammatory, and anti-fibrotic genes.” Nrf2 preserves the expression of vascular endothelial growth factor and prevents RV failure without modifying lung angioproliferation.
The Dietary Supplement Protandim® Decreases Plasma Osteopontin and Improves Markers of Oxidative Stress in Muscular Dystrophy Mdx Mice
HARVARD UNIVERSITY
| Click here for full abstract. |
Informa Healthcare (2010)
Abstract: “Oxidative stress is a significant pathologic factor in DMD.” After 6 months of Protandim® supplementation, a 48% decrease in plasma TBARS was seen, plasma OPN [osteopontin] was decreased by 57%, plasma antioxidant enzyme PON 1 activity was increased by 35%, and 38% less signal abnormality was shown.
The Chemopreventive Effects of Protandim: Modulation of p53 Mitochondrial Translocation and Apoptosis during Skin Carcinogenesis
LOUISIANA STATE UNIVERSITY
| Click here for full abstract. |
PLoS ONE Journal (2010)
Abstract: Our results that suppression of p53 and induction of MnSOD may play an important role in the tumor suppressive activity of Protandim.
Results: MnSOD, highly inducible by Protandim, is effective in the suppression of tumor promotion. Previous findings were confirmed and extended that “Protandim® modulates tumorigenesis via the induction of endogenous antioxidant enzymes.” Additionally, “Protandim utilizes multiple mechanisms to modulate cell proliferation and aptosis in vivo and in vitro, which both contribute to tumorigenesis, therapies in chemoprevention.”
Protandim Attenuates Intimal Hyperplasia in Human Saphenous Veins Cultured Ex Vivo via a Catalase-Dependent Pathway
OHIO STATE UNIVERSITY
| Click here for full abstract. |
Free Radical Biology and Medicine (2010)
Abstract: Human saphenous veins (HSV) are widely used for bypass graphs despite their relatively low long-term patency. The role of reactive oxygen species (ROS) signaling in intima hyperplasia (IH), an early stage pathology of vein graft disease, and to explore the potential therapeutic effects of up-regulating endogenous antioxidant enzymes in segments of HSV cultured ex vivo in an established ex vivo model of HSV IH. Protandim®, known to activate Nrf2 and increase the expression of endogenous antioxidant enzymes in several in vitro and in vivo models, was used in this study.
Results: Protandim® inhibits the formation of IH and the increase in cellular proliferation in HSV cultured ex-vivo. Further, Protandim® attenuates rise in superoxide (O) levels in HSV, attenuates rise in lipid peroxidation (4-HNE) levels in HSV, enhances increases in the activities of HO-1, total SOD and catalase in HSV, enhances the protein level and immunofluorescent intensity of catalase in HSV, blocks medial thickening as well as cellular proliferation in established ex-vivo model of the early stages of vein-graft disease. These abilities of Protandim®, as demonstrated in HSV harvested from patients undergoing coronary artery bypass grafting, makes it an attractive candidate for future consideration as a pharmacological treatment of vein-graft failure.
The Role of Manganese Superoxide Dismutase in Skin Cancer
LOUISIANA STATE UNIVERSITY
| Click here for full abstract. |
Enzyme Research (2011)
“The induction of antioxidant enzymes via dietary administration of Protandim® modulates both TPA-mediated cell proliferation and p53-mediated apoptotic signaling. Therefore, it can be concluded that oxidative stress forms a mechanistic linkage between cell proliferation, inflammation, and apoptosis, suggesting that potent multimodal antioxidant inducers may potentially be utilized with conventional chemotherapeutics.”
Universities and Institutions around the world continue to initiate and fund their own trials investigating its anti-aging and health-promoting capabilities. These include:
- Massachusetts General Hospital, Harvard Medical School
- Children’s Hospital, Denver
- University of Florida
- University of Kentucky
- University of Michigan
- University of Minnesota
- Vanderbilt University
- Glamorgan University, Wales
- Sahigrenska University Hospital, Goteborg, Sweden
- University of Toronto/St. Michelle’s Hospital, Canada
- University Hospital, Brno, Czech Republic
- Mexican Institute of Social Security, Mexico City
- National Institute of Arthritis and Musculo Skeletal and Skin Diseases
You still have doubts?
If you are still contemplating taking another competing product. Visit https://PubMed.com and type the competing product in and see if there are any Peer-Reviewed studies published. Any company with substantial claims should submit a Peer-Reviewed study so the community knows the claim is valid.